Purpose: To investigate the efficacy of the double inversion recovery sequence (DIR) in breast cancer detection.
Materials And Methods: Fifty-six patients with biopsy-proven breast cancers underwent preoperative breast MRI, including sagittal DIR and contrast-enhanced T1-weighted images (CE-T1WI). Twenty-four of the 56 patients additionally underwent sagittal T1WI and T2WI. The signal intensities of the lesion (L) and ipsilateral normal breast tissue (N) were measured. The lesion-to-normal ratio (LNR) was defined as LNR = 100(L-N)/N. We compared LNRs among the four sequences, and then assessed the differences of LNRs between CE-T1WI and DIR in each pathologic subgroup (IDC and non-IDC group). Multiple regression analysis was performed to identify predictors of the signal-to-noise ratios (SNR) of the normal tissue or lesion and LNRs.
Results: The mean LNR did not differ significantly between DIR (58.65 ± 71.55) and CE-T1WI (59.78 ±31.04), nor did the LNRs between DIR and CE-T1WI in the two subgroups. The LNRs of DIR did not differ significantly between the two subgroups (P = 0.247). The SNR of lesions in DIR was correlated with the intraductal component percentage (r(2) = 0.485, P = 0.037).
Conclusion: DIR and CE-T1WI showed similar tumor detection efficacy, and DIR could complement dynamic MRI for detecting breast cancer without a contrast agent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmri.24115 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion.
Cancer Treat Rev
January 2025
Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Electronic address:
Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely affecting drug compliance. Topical estrogen (TE) has been proposed for symptom management, given its' local application and presumed reduced bioavailability, however its oncological safety remains uncertain.
View Article and Find Full Text PDFDetectability of Al18F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer.
Clin Nucl Med
January 2025
From the Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine; Peking University Cancer Hospital and Institute, Beijing, China.
Purpose: The aim of this study was to compare Al18F-NOTA-HER2-BCH and 18F-FDG for detecting nodal metastases in patients with HER2-positive breast cancer on PET/CT.
Patients And Methods: In this retrospective study, 62 participants with HER2-positive breast cancer underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT. Participants were pathologically confirmed as HER2-positive (IHC 3+ or IHC 2+ with gene amplification on FISH).
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
J Clin Oncol
January 2025
Breast Surgery, Kyoto University Graduate School of Medicine, Shogoin Sakyo-ku, Kyoto, Japan.
In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months.
View Article and Find Full Text PDFGenomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.
JCO Precis Oncol
January 2025
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Purpose: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics.
Methods: This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0.
Validation of a Single Item Measure for Financial Toxicity Screening in Patients With Breast Cancer.
JCO Oncol Pract
January 2025
College of Population Health, Thomas Jefferson University, Philadelphia, PA.
Purpose: Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen remains an unmet need. We evaluated item 12 ("My illness has been a financial hardship to my family and me") of the COmprehensive Score for Financial Toxicity (COST) measure as a single-item FT screening measure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!